Planegg/Martinsried, November 2, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the 29th Annual BIO-Europe taking place November 6-8, 2023, in Munich and present at the Deutsches Eigenkapitalforum to be held November 27-29, 2023, in Frankfurt.
Date: November 6-8, 2023
Location: Trade Fair Center Messe München
Members of Medigene’s Corporate Development team will be available for one-on-one meetings at the event.
Corporate presentation – Deutsches Eigenkapitalforum 2023
Date and time: Monday, November 27, 2023, 2:05 pm – 2:35 pm (local time), conference room London
Location: Steigenberger Airport Hotel Frankfurt
Members of Medigene’s management team will be available for one-on-one meetings at the event.
Please contact Julia von Hummel of MC Services at Julia.vonHummel@mc-services.eu to schedule a meeting at either one of the conferences.
— end of press release —
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its End-to-End Platform, built on multiple proprietary and exclusive TCR generation and optimization, as well as product enhancement technologies, allows Medigene to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for safety, efficacy and durability. For more information, please visit: www.medigene.com
Phone: +49 89 2000 3333 01
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (firstname.lastname@example.org). We will then delete your address from our distribution list.